TRAVERE THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-34.8M | $-37.1M | $2.7M | $25.7M | $-12.8M | $-41.2M | $-60.3M | $-54.8M |
| Depreciation & Amortization | $4.2M | $25.2M | $18.1M | $15.8M | $14.0M | $12.8M | $12.1M | $11.2M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $3.8M | $24.8M | $17.8M | $15.4M | $13.6M | $12.4M | $11.6M | $10.8M |
| Stock-Based Compensation | $21.8M | $16.1M | $11.5M | $11.3M | $10.6M | $11.5M | $9.2M | $8.0M |
| Net Cash from Operating Activities | $58.1M | $-40.4M | $60.7M | $14.3M | $5.0M | $-42.2M | $-35.7M | $-42.5M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-206.3M | $21.5M | $-104.8M | $86.6M | $4.9M | $41.3M | $-80.3M | $46.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $187.5M | $4.2M | $26.7M | $-65.3M | $1.5M | $3.7M | $139.1M | $46.0K |
| Net Change in Cash | $39.4M | $-14.7M | $-17.9M | $35.8M | $13.3M | $3.4M | $22.1M | $4.1M |
| Free Cash Flow | — | — | — | — | — | — | — | $-42.5M |